Clinical Outcomes And Safety Profile Of Mitomycin Intravascular Chemoembolization (Mice) To Treat Corneal Neovascularization: 1 Year Results
Published 2026 - 44th Congress of the ESCRS
Reference: POCOR515 | Type: Free paper | DOI: 10.82333/ttkm-v315
Authors: Mr Nitin Rangu 1 , Dr Karanpreet Singh Multani 1 , Dr Kamran Riaz* 1
1Ophthalmology,Dean McGee Eye Institute,Oklahoma City,United States
Purpose
To evaluate the clinical outcomes and safety profile of Mitomycin intravascular chemoembolization (MICE) to treat corneal neovascularization (NV).
Setting
Single tertiary academic center.
Methods
A 100-eye retrospective case series from nine international centers undergoing MICE for corneal neovascularization (2021–2025). Data included BCVA, complications, and NV regression by surgeon and ImageJ analysis.
Results
Preoperative mean BCDVA was 0.9 ± 0.65. At 3 months post-MICE, BCDVA was 0.8 ± 0.58 (p = 0.128), improving significantly at 6–12 months (0.7 ± 0.55, p = 0.012) and 12+ months (0.5 ± 0.51, p = 0.381). Complications included corneal thinning (n = 2) and additional surgery (n = 25). No infections or intraocular elevations were noted. KNV regression was observed in 81.4% of eyes at 6–12 months and 65.1% at 12+ months. ImageJ analysis showed a mean vascularization decrease of –55.6% ± 15.2 at 6–12 months and –32.6% ± 14.5 at 12+ months.
Conclusions
MICE is effective in the management of corneal vascularization. Limited complications and significant BCDVA improvement were demonstrated.